Bioprinting is rapidly moving from research labs into commercial reality, and it is reshaping how the pharmaceutical and ...

From the 12th to the 15th, the JP Morgan Healthcare Conference, widely regarded as the world’s largest pharmaceutical and ...

As we head into the 2026, let's take a look at biotech licensing deals and M&As that were inked in December 2025.

Over the past few years, Axsome Therapeutics has made slow and steady clinical and regulatory progress. The company's lineup ...

A new year always brings new challenges, and there will be many of them facing the pharmaceutical industry and policymakers ...

The New Year's Champagne turned flat for Madrigal Pharmaceuticals ( MDGL 5.01%) on Tuesday. Investors traded out of the ...

Focusing on 2026 as a starting point, PwC has laid out several “strategic imperatives” pharma companies ought to pursue this ...

1) Innovent has positioned itself at the forefront of China’s GLP-1 market with Mazdutide, the first-in-class dual GCG/GLP-1 receptor agonist approved for obesity and overweight in June 2025.

Patented Green Extraction Technology Transforms Black Soldier Fly Waste Into Pure Insulin at 50% of Synthetic Insulin Cost Half-price natural Insulin is finally within reach, thanks to generational ...

Pharma stocks are back in focus as obesity drugs, HIV prevention and biotech deal activity shape the outlook heading into ...

Amgen is committed to reducing drug costs, expanding its AmgenNow program, and investing in US manufacturing to gain tariff ...

Lynn Mehler will chair Paul Hastings' life sciences regulatory practice. She and Phil Katz join the firm from Hogan Lovells.